LivaNova (LivaNova) EBIT per Share : $-0.40 (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is LivaNova EBIT per Share?

LivaNova's EBIT per Share for the three months ended in Dec. 2023 was $-1.44. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.40.

During the past 12 months, the average EBIT per Share Growth Rate of LivaNova was -59.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for LivaNova's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of LivaNova was 52.60% per year. The lowest was -47.00% per year. And the median was 9.70% per year.

LIVN's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 6.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

LivaNova's EBIT for the three months ended in Dec. 2023 was $-79 Mil.

LivaNova EBIT per Share Historical Data

The historical data trend for LivaNova's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova EBIT per Share Chart

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-3.58

-6.32

-1.47

-0.50

-0.41

LivaNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.37	0.43	0.37	0.24	-1.44

LivaNova EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

LivaNova's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.373	/	54.212
=	-0.41

LivaNova's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-78.675	/	54.527
=	-1.44

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

LivaNova (NAS:LIVN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

LivaNova EBIT per Share Related Terms

Thank you for viewing the detailed overview of LivaNova's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

LivaNova (LivaNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Executives

James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck	officer: Chief Human Resources Officer	20 EASTBOURNE TERRACE, LONDON X0 W2 6LG